Breast-Conserving Therapy Versus Radical Mastectomy for Early Breast Cancer: 20-Year Follow-Up

Elena Alexandrova1*, Sonya Sergieva2, Petya Kostova1, Dimiter Katsarov1, Margarita Taushanova3, George Kalaidjiev1 and Angel Milev1

1Department of Thoracic Surgery, National Oncological Hospital, Bulgaria
2Sofia Cancer Center, Bulgaria
3Nadejda Hospital, Bulgaria

*Corresponding Author: Prof. Elena Alexandrova, MD, PhD, Department of Thoracic Surgery, National Oncological Hospital, "Plovdivsko Pole" Street 6, Sofia 1756, Bulgaria.

Received: July 14, 2016; Published: August 31, 2016

Abstract

Purpose: The aim of this clinical study was to compare breast-conserving therapy (BCT) and radical mastectomy (RM) in the treatment of early breast cancer.

Materials and Methods: From March 1986 to the end of 1989, 117 women with a breast tumour of up to 2 cm in size were included in this study; 66 women had a quadrantectomy, while 51 had a radical mastectomy. Full axillary dissection was performed in all patients, while adjuvant chemotherapy with Cyclophosphamide, Methotrexate and Fluorouracil was conducted in node-positive patients. Radiation to the remaining breast parenchyma consisted of external-beam therapy, with or without regional irradiation, without boost to the tumour bed.

Results: The follow-up of patients in the two treatment groups was limited to 240 months. The mean period of observation (± SD) was 201.34 months (54.12 ± 226.5) for the BCT and 195.84 months (35.1 ± 226.5) for the patients with radical mastectomy. No significant difference in overall survival (p = 0.5410), distant metastases (Fisher’s exact test, p = 0.117) and contralateral breast cancers (Fisher’s exact test, p = 0.809) between the two groups was established. The average survival for patients in both study groups was also statistically insignificant (211.4 months with 95% Confidence Interval 197.9 ÷ 224.9 in the quadrantectomy group and 204.0 months with 95% Confidence Interval 188.0 ÷ 219.9 in the radical mastectomy group, Log Rank, p = 0.342).

Conclusion: Our data supports the view that breast-conserving surgery and irradiation is equivalent to mastectomy in terms of long-term survival for patients with stage I breast cancer.

Keywords: Breast cancer; 20-year follow-up; Conserving therapy; Radical mastectomy

Introduction

For almost a century, radical mastectomy, introduced by Halsted WS, was the method of choice for the treatment of breast cancer, despite the stage of the disease and the age of the woman. During that time period, the idea of breast conservation was highly unpopular and widely refuted. This sentiment was clearly expressed in the words of the famous surgeon Urban, who, during one of his lectures in front of the Society of Surgical Oncology in 1976, expressed regret that “the rational way of treating breast cancer is substituted by the woman’s vanity” [1].

Currently, these beliefs are only of historical value. In the early 1990s, breast conservation surgery (BCT) followed by radiotherapy was accepted as the standard treatment for early diagnosed tumors of the breast [2]. Dramatic changes occurred as a result of the immense amount of research conducted in oncological centers throughout Europe and North America. Numerous clinical studies comparing breast...
Breast-conserving approaches and radical mastectomy proved the same efficacy as far as overall survival was concerned [3-8]. The main argument for a critical valuation of the data was the fact that it was all preliminary due to the short follow-up period of patients. To prove the effectiveness of new treatment methods, patients with small tumors should be followed up for a long period of time, even for decades. The aim of this clinical study was to compare breast-conserving therapy (BCT) and radical mastectomy (RM) in the treatment of early breast cancer.

In 1986, a few years after research was initiated in Milan, the National Oncological Centre in Sofia began a study whose purpose was to note the long-term treatment results of performed quadrantectomy with post-operative radiotherapy. We closely followed 124 patients over a 20-year period and are now reporting the latest results.

**Materials and Methods**

Patient recruitment in the study started in March 1986 and finished at the end of 1989 with the enrolment of 124 patients of up to 60 years of age with invasive breast tumors up to 2 cm in size (T1) and a clinically negative axilla (N0). Patients with in-situ tumors, pregnant women, and women with a positive family history for breast cancer were not included in the study.

The clinical staging of the disease was performed in accordance with the TNM classification of the International Union Against Cancer [9] (revision, corresponding to the year of the diagnosis was given). Seven patients (8.68%) were excluded due to incorrect staging. The remaining 117 patients were divided into two types of surgical treatment methods: organ-sparing (66 patients) and mastectomy (51 patients).

The distribution of the patients in the corresponding groups is shown in Figure 1.

![Figure 1: Patient's distribution to breast-conserving.](image)

The surgical treatment option of the patients in the organ-conserving group was classical quadrantectomy, as described by Veronesi [9]. The primary tumor was excised with an area of 2-3 cm of surrounding healthy parenchyma, with the underlying fascia of the large pectoral muscle and the overlying skin. A mandatory condition for conserving the breast was the achievement of tumor-free resection margins. In case of positive margins, partial resection was not performed, but the patient was redirected towards a radical mastectomy.

The patients from the radical mastectomy group were surgically operated according to the original Halsted method [10], which was used in 44 of the patients. Seven patients of that group had mastectomy performed using the method of Patey [11].

Following the treatment policy of the Centre during this time period, all 117 patients underwent axillary dissection. In the patients with medial tumor localization, a parasternal lymph node biopsy was performed for the purpose of disease staging.

The patients with quadrantectomy underwent radiation of the residual parenchyma with doses of up to 50 Gy without an additional dose in the tumor bed. Twenty-one patients with histologically proven metastatic lymph nodes received a radiation dose of 40 Gy to the lymph nodes in the region of mammae interna and the supraclavicular lymph nodes.

Adjuvant chemotherapy was performed based on the pathological characteristics of the primary tumor. The main chemotherapy scheme used at the time was a combination of cyclophosphamide 100 mg/m² taken per os daily from the 1st to the 14th day, methotrexate 40 mg/m² and fluorouracil 600 mg/m² intravenously on the 1st and the 8th day, for a total of 6 courses. This scheme was applied to 21 (31.8%) of the patients with quadrantectomy and in 13 (25.4%) of the patients with radical mastectomy.

Adjuvant hormonal therapy was performed in 35 (53%) of the patients with quadrantectomy and 26 (50.1%) of the patients with mastectomy, based on the data obtained from hormone receptor studies.

Tamoxifen in a dose of 20 mg daily was given for a period of 5 years. In young women with regular menstrual cycles, surgical castration and, less often, laser castration (in 9 patients) was performed before the administration of hormonal therapy with tamoxifen, following the treatment guidelines of the period.

The patients were monitored at a 4-month interval during the first two years after completion of the treatment and afterwards at a 6-month interval. The follow-up examination included a yearly clinical examination, mammogram, conventional lung X-Ray, abdominal ultrasound, and bone scintigraphy.

The main objective of this long-term analysis was to compare radical mastectomy and breast conserving therapy (BCT) with respect to local recurrences, distant metastases and overall survival.

The major prognostic factors (age, menopausal status, axillary lymph-node status, histologic type, tumor grade, ER/PR status and adjuvant treatment) were compared using a Fisher’s exact test [12].

Overall survival was estimated using the Kaplan-Meier method, and the obtained results of mastectomy and BCT were compared using the Log-rank test [13].

Results

The average age (SD ±) of the patients from the quadrantectomy group was 49.58 ± 10.1 years, while that of the radical mastectomy group was 48.55 ± 8.4 years, (p = 0.666).

The maximum follow-up period for the patients from both groups was limited to 240 months. The average follow-up period (SD ±) of patients with quadrantectomy was 201.34 months (54.12 ± 226.5), and 195.84 months (35.1 ± 226.5) for patients with radical mastectomy.

The main clinical and histological characteristics of patients from both treatment groups, resulting from the oncological condition, are shown in Table 1.

Comparison of the main prognostic indicators of patients from both treatment groups failed to find statistically significant differences in any of the aforementioned factors (chi-square test, p > 0.05). This gives us reason to assume that patients from both monitored groups are similar and that the results of both administered treatment options can be correlated using the following measures: survival, local recurrences, and distant metastasis. The treatment outcome for this disease after organ preservation and radical mastectomy is shown in Table 2.

At the end of the 20-year follow-up period, the number of patients who were still alive was 62.1% of patients with quadrantectomy and 60.8% of patients with radical mastectomy (p = 0.9426).
<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Breast conserving therapy (N = 66)</th>
<th>Mastectomy (N = 51)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td>0.666</td>
</tr>
<tr>
<td>&gt; 35 years</td>
<td>17 (25.7%)</td>
<td>11 (21.6%)</td>
<td></td>
</tr>
<tr>
<td>&lt; 36 years</td>
<td>49 (74.3%)</td>
<td>40 (78.4%)</td>
<td></td>
</tr>
<tr>
<td>Menopausal status</td>
<td></td>
<td></td>
<td>0.703</td>
</tr>
<tr>
<td>Pre-menopausal</td>
<td>26 (39.4%)</td>
<td>18 (35.3%)</td>
<td></td>
</tr>
<tr>
<td>Post-menopausal</td>
<td>40 (60.6%)</td>
<td>33 (64.7%)</td>
<td></td>
</tr>
<tr>
<td>Axillary node status</td>
<td></td>
<td></td>
<td>1.000</td>
</tr>
<tr>
<td>N0</td>
<td>42 (63.6%)</td>
<td>33 (64.7%)</td>
<td></td>
</tr>
<tr>
<td>N+</td>
<td>24 (36.4%)</td>
<td>18 (35.3%)</td>
<td></td>
</tr>
<tr>
<td>Histological kind</td>
<td></td>
<td></td>
<td>0.849</td>
</tr>
<tr>
<td>Invasive ductal</td>
<td>42 (63.7%)</td>
<td>34 (66.7%)</td>
<td></td>
</tr>
<tr>
<td>Invasive lobular</td>
<td>17 (25.7%)</td>
<td>11 (21.6%)</td>
<td></td>
</tr>
<tr>
<td>Others*</td>
<td>7 (10.6%)</td>
<td>6 (11.7%)</td>
<td></td>
</tr>
<tr>
<td>Grading</td>
<td></td>
<td></td>
<td>0.617</td>
</tr>
<tr>
<td>G2</td>
<td>22 (33.3%)</td>
<td>7 (13.7%)</td>
<td></td>
</tr>
<tr>
<td>G3</td>
<td>44 (66.7%)</td>
<td>44 (86.2%)</td>
<td></td>
</tr>
<tr>
<td>ER- status</td>
<td></td>
<td></td>
<td>1.000</td>
</tr>
<tr>
<td>Positive</td>
<td>47 (71.2%)</td>
<td>37 (72.5%)</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>19 (28.7%)</td>
<td>14 (27.4%)</td>
<td></td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>21 (31.8%)</td>
<td>13 (25.4%)</td>
<td></td>
</tr>
<tr>
<td>Hormonal therapy</td>
<td>35 (53%)</td>
<td>26 (50.1%)</td>
<td></td>
</tr>
</tbody>
</table>

*Other histological kinds: tubular, papillary, gelatinous.

**Table 1:** Patients' characteristics.

<table>
<thead>
<tr>
<th></th>
<th>Breast-conserving treatment (n = 66)</th>
<th>Radical mastectomy (n = 51)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alive</td>
<td>41</td>
<td>31</td>
<td>0.9426</td>
</tr>
<tr>
<td>Local relapse</td>
<td>12</td>
<td>4</td>
<td>0.174</td>
</tr>
<tr>
<td>Distant metastases</td>
<td>21</td>
<td>18</td>
<td>0.698</td>
</tr>
<tr>
<td>Contralateral breast carcinoma</td>
<td>11</td>
<td>10</td>
<td>0.809</td>
</tr>
</tbody>
</table>

**Table 2:** Incidence of events over the 20-year period within the two groups of patients.

Twelve (18.2%) local recurrences were found in the group with breast conserving therapy and 4 (7.8%) in the group with radical mastectomy, (p = 0.1065). Other than the higher frequency of recurrence after quadrantectomy and radiation, there is no significant difference between the two treatment groups due to the small number of cases.

Eleven contralateral breast cancers (16.6%) were found in the group with quadrantectomy versus 10 (19.6%) in the group with radical mastectomy (p = 0.809).

Breast-Conserving Therapy Versus Radical Mastectomy for Early Breast Cancer: 20-Year Follow-Up


Chest wall recurrences after mastectomy arise relatively early on, with a mean period of 67.25 months after the treatment (SD ± 74.13). In addition, we noticed a very late onset of recurrences in the chest wall after a Halsted mastectomy, i.e., after 18 years.

Our results failed to show any significant differences between local recurrences, distant metastases and contralateral carcinoma, which results in the observed survival.

Recurrences appeared in the residual parenchyma throughout the whole follow-up period, with a post-operative average of 74.79 months (SD ± 60.57).

The recurrence distribution in the quadrants of the breast shows that in only 5 (41.6%) of the cases, the recurrence was localized in close proximity to the operative cicatrices. These recurrences arose early after treatment completion, with an average of 37.45 months post treatment, and tended to manifest as diffuse growths or skin infiltrations.

The remaining seven recurrences (58.4%) were located in places further away from the infiltrated quadrant. They arose significantly later on, with an average of 98.79 months after treatment, and their occurrence was noted after the tenth and fifteenth years following the end of therapy.

All recurrences of the chest wall were confined to the surgical cicatrix and the proximal flap. All were locally operable, but one was multiple.

Development of distant metastases was observed in almost the same number of patients from both comparison groups: 21 patients (36.8%) from the group with quadrantectomy and 18 patients (35.3%) from the group with radical mastectomy (Fisher’s exact test p = 0.117). Furthermore, the average period of time for the development of distant metastases in the two groups did not differ significantly (69 months in patients from the quadrantectomy group and 63 months in patients from the radical mastectomy group (Fisher’s exact test p = 0.755).

The distribution of the distant metastases in all 117 patients, and thus from both treatment groups, as based on organ site is as follows: bones in 16 patients (13.7%), lungs in 13 patients (11.1%), the liver in 5 patients (4.3%), the pericardium in 1 patient (0.8%), and multiple metastases noted simultaneously in the lung, brain, pleura and bones in 11 patients (9.4%).

The frequency of contralateral tumors in the two treatment groups was also similar: 11 (16.6%) in the organ-sparing group and 10 (19.6%) in the radical mastectomy group (Fisher’s exact test p = 0.809).

Figure 2: Incidence of local recurrence, distant metastases and contralateral breast carcinoma in patients, treated with breast conserving surgery (BCS) and radical mastectomy (RM).
Breast-Conserving Therapy Versus Radical Mastectomy for Early Breast Cancer: 20-Year Follow-Up

The median overall survival did not differ significantly between the two groups (211.4 months with a 95% confidence interval 197.9-224.9 in the organ-sparing treatment group and 204.0 months with 95% confidence interval 188.0-219.9 in the radical mastectomy group, Log rank p = 0.759).

<table>
<thead>
<tr>
<th>Treatment groups</th>
<th>AS* (Months)</th>
<th>SE (Months)</th>
<th>95% CI (Months)</th>
<th>Observation period (Months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast-conserving</td>
<td>211.4</td>
<td>6.890</td>
<td>197.9-224.9</td>
<td>240</td>
</tr>
<tr>
<td>treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radical mastectomy</td>
<td>204.0</td>
<td>8.142</td>
<td>188.0-219.9</td>
<td>240</td>
</tr>
</tbody>
</table>

**Table 3: Average survival after breast conserving treatment (BCT) and radical mastectomy (RM).**

AS* Average Survival, SE-standard error, CI-Confidence Interval

The survival functions, compared using the Kaplan–Meier method, do not detect a significant difference between patients with organ preservation and those with radical mastectomy. Patients were followed for 240 months after the completion of therapy (Log rank test p = 0.5410).

![Overall survival of patients followed for 20 years after breast conserving surgery (BCS) and radical mastectomy (RM).](image)

**Figure 3: Overall survival of patients followed for 20 years after breast conserving surgery (BCS) and radical mastectomy (RM).**

A 20-year survival was noted in 56% of the group with radical mastectomy and 58% of the group with breast-conserving treatment (p = 0.5410).

**Discussion**

The results from this study demonstrate the same overall survival rates for women with an early stage of breast cancer, whether treated with quadrantectomy and post-operative radiation therapy or with radical mastectomy (p = 0.5410).

Our standpoint is based on the results collected over a span of 20 years, along with data obtained by other well-known research studies, published after the year 2002.

The closest correlation was found with the latest Milan-I [14] data (60.8%, versus 62.1%, p = 0.9), which is most likely due to incorporating the same criteria for patients along with using the same surgical methods for the treatment of the primary tumor (quadrantectomy and radical mastectomy using the Halsted method).

Our latest overall survival results are comparable to the most extensive data-based comparison study conducted, that is, The National Surgical Adjuvant Breast and Bowel Project (NSABP B-06) [15].

Although in that study, lumpectomy and radiation therapy are compared to a modified radical mastectomy, the twenty-year survival rate of both groups was statistically the same (46% in the group with lumpectomy and radiation therapy versus 47% in the group with modified mastectomy, p = 0.67).

Similar findings were also noted in the latest results of the DBCG-82TM protocol [16] (53.7% in the conservative group versus 49.1% in the mastectomy group, p = 0.24) and further proven by the data from the European Organization for Research and Treatment of Cancer (EORTC) 10801 (39.1% versus 44.5%, p = 0.42).

All of the aforementioned well-known studies, as well as the present study, show the same overall survival rate in patients treated with either of the two different local methods, despite the different criteria incorporated or the elected treatment procedure.

Therefore, the results of the current study support the main viewpoint for systemic therapy and the fact that the prognosis of breast cancer is linked to the presence or the absence of occult foci arising from metastatic cells, not from the local treatment option.

The results of this study provide additional evidence that the preservation of the breast does not negatively alter patient survival and contribute to the elimination of existing doubts in regards to the effectiveness of organ preservation methods.

The frequency of local recurrences in our study is comparable with the results of other studies with a 20-year follow-up period [14-17].

The close correlation in the frequency of local recurrences after a quadrantectomy and 50 Gy post-operative radiation (18.2%) and a contralateral tumor in this group (16.7%) supports the view that some part of the recurrences in the residual parenchyma are not the result of a residual tumor but rather a congenital tendency in developing breast cancer.

The differences in cumulative frequency of local recurrences is due to the different criteria used for the incorporation of patients, the different surgical procedures utilized, and the treatment dose used in the different studies.

**Table 4: Overall survival rate after BCT and RM in studies with a 20-year follow-up period.**

<table>
<thead>
<tr>
<th>Studies</th>
<th>Type of local treatment</th>
<th>Frequency of local recurrences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Milan-I14</td>
<td>quadrantectomy with radiation therapy 50 + overdose 10 Gy</td>
<td>8.8%</td>
</tr>
<tr>
<td>NSABP-B0615</td>
<td>Tumorectomy with radiation therapy 50 Gy</td>
<td>14.3%</td>
</tr>
<tr>
<td>EORTC 1080116</td>
<td>lumpectomy, radiation therapy and 25 Gy additional dose</td>
<td>20%</td>
</tr>
<tr>
<td>NCI17</td>
<td>a wide local excision and radiation therapy 50 Gy</td>
<td>up to 22%</td>
</tr>
<tr>
<td>NCC- Sofia</td>
<td>quadrantectomy with radiation therapy dose 50 Gy</td>
<td>18.2%</td>
</tr>
</tbody>
</table>

**Table 5: Frequency of local recurrences after organ-preserving therapy in patients followed for 240 months.**

The frequency of local recurrences in patients treated with the selected methods did not differ significantly.

Our data confirm the proposition that the residual parenchyma after organ-preserving resections has the potential for the development of local recurrence; that is, organ-preserving operations are associated with a higher frequency of local recurrences (12 in the residual parenchyma versus 4 in the chest wall).

In our patients, recurrences in the residual parenchyma completely correlate with the model, which has been described in great detail by the researchers of IGR [8], who were the first to describe the effect of prolonged follow-up of patients with breast-conserving treatment. After a 26-year follow-up of patients with organ-preserving operations, these researchers proved that there is no real stabilization of the risk of recurrence, as is observed in patients with mastectomy.

Our data also demonstrate that recurrences after a quadrantectomy can and do develop throughout the entire follow-up period, while recurrences in the chest wall after a radical mastectomy usually occur in the first three years (up to the 31st month).

The long-term follow-up of patients gives us the unique opportunity to also observe exceptions, as in the case of recurrence in the chest wall, which arose 18 years (216 months) after a Halsted mastectomy.

The similarities in the frequency of distant metastases in the two treatment groups (36.8% in the quadrantectomy group versus 35.2% in the radical mastectomy group, $p = 0.117$) and the undifferentiated period of time it takes for their appearance (63 months for the recurrences in the chest wall and 69 months for the recurrences in the residual parenchyma, $p = 0.755$) show that dissemination is a process that occurs and develops in the same manner, despite the local treatment plan implemented.

An important clinical conclusion drawn from the current study is the absence of an oncogenic effect from the conducted radiation therapy. It is widely known that one of the arguments against breast preservation has been the idea that a significant ionizing radiation dose, which destroys the residual tumor cells, could lead to a neoplastic transformation in the normal cells of the residual breast tissue and in the contralateral breast. If we accept the notion that during postoperative radiation of the residual parenchyma, the contralateral breast receives a radiation dose of 0.5 Gy in its most lateral portion and 10-15 Gy in the medial portion, then we can expect a drastic increase in the contralateral cancers in the group with organ-preservation treatment.

The similarity in the frequency of contralateral tumors between the group with organ-preservation treatment and that with radical mastectomy (16.7% vs 19.6%, $p = 0.809$) suggests the idea that the implemented radiation dose does not have a carcinogenic effect. Similar conclusions have also been reported by other authors who, after a 20-year study, have not found sufficient proof for radiation-induced carcinoma [18, 19].

Despite a few limitations connected with the retrospective character of the study and the small number of patients, our results are statistically significant due to the homogeneity of the groups and the strict criteria used to include the patients. This permits us to report our conclusions.

**Conclusion**

A twenty-year follow-up study of our patients proves that the organ-preservation procedures, which provide patients with a high quality of life, are a sure and safe method for early breast cancer treatment. Furthermore, the residual parenchyma is a potential place for the development of local recurrences, which requires the patients to be followed for decades or even throughout their remaining lives.

**Bibliography**


Volume 3 Issue 4 August 2016
© All rights reserved by Elena Alexandrova., et al.